Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Format:	Artigo
Language:	Inglês
Published:	BioMed Central 2012
Subjects:	Research
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3323440/ https://ncbi.nlm.nih.gov/pubmed/22390313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-4
Tags:	Add Tag No Tags, Be the first to tag this record!

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Similar Items